17,261 trials
Cancer
Primary: Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib Monotherapy — 3; 19; 12; 16 Participants
Inguinal Hernia
Primary: Safety and Tolerability: Event of SAE and Treatment-related Severe AE — 2; 1; 2; 2 Event
Fatty Liver · Non-Alcoholic Steatohepatitis · Liver Diseases
Primary: Change From Baseline in Mean Liver Fat — -3.18; -3.41; -0.09 Abs. % Change from Baseline Liver Fat — p=0.0655
Ichthyosis Vulgaris
Primary: Treatment Success — 21; 28 Participants
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Alagille Syndrome
Primary: Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18 — -21.73; 95.55 μmol/L — p=0.0464
Ovarian Cancer · Epithelial Ovarian Cancer · Fallopian Tube Cancer
Primary: Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study) — 388; 174; 160…
Central Venous Catheter Thrombosis · Central Venous Catheter Associated Bloodstream Infection
Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants
Herpes Labialis
Primary: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment — 21.8; 16.4; 19.9; 78.2 percentage of partcipants…
Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Domain Score at Week 2 — -3.64; -3.15 Units on a scale — p=0.39
Herpes Simplex Type 2
Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Age-Related Macular Degeneration
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 24 — 4.35; 0.87; -1.70 letters
Cervical Spinal Cord Injury · Spine Injury · Spinal Cord Trauma
Primary: Number of Adverse Events Within 1 Year (365 Days) That Are Related to AST-OPC1 Injection — 92; 122; 133; 118 Adverse Events
C3 Glomerulonephritis · Dense Deposit Disease · C3 Glomerulopathy
Primary: Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15 — 0.32; 0.56; 0.48; 0.35 g/L